These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 24519975)

  • 1. Nerve growth factor metabolic dysfunction in Down's syndrome brains.
    Iulita MF; Do Carmo S; Ower AK; Fortress AM; Flores Aguilar L; Hanna M; Wisniewski T; Granholm AC; Buhusi M; Busciglio J; Cuello AC
    Brain; 2014 Mar; 137(Pt 3):860-72. PubMed ID: 24519975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion.
    Cooper JD; Salehi A; Delcroix JD; Howe CL; Belichenko PV; Chua-Couzens J; Kilbridge JF; Carlson EJ; Epstein CJ; Mobley WC
    Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10439-44. PubMed ID: 11504920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome.
    Hunter CL; Isacson O; Nelson M; Bimonte-Nelson H; Seo H; Lin L; Ford K; Kindy MS; Granholm AC
    Neurosci Res; 2003 Apr; 45(4):437-45. PubMed ID: 12657457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nerve growth factor metabolic dysfunction in Alzheimer's disease and Down syndrome.
    Iulita MF; Cuello AC
    Trends Pharmacol Sci; 2014 Jul; 35(7):338-48. PubMed ID: 24962069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
    Pentz R; Iulita MF; Ducatenzeiler A; Videla L; Benejam B; Carmona‐Iragui M; Blesa R; Lleó A; Fortea J; Cuello AC
    Alzheimers Dement; 2021 Apr; 17(4):605-617. PubMed ID: 33226181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dual mechanism linking NGF/proNGF imbalance and early inflammation to Alzheimer's disease neurodegeneration in the AD11 anti-NGF mouse model.
    Capsoni S; Brandi R; Arisi I; D'Onofrio M; Cattaneo A
    CNS Neurol Disord Drug Targets; 2011 Aug; 10(5):635-47. PubMed ID: 21631402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration.
    Salehi A; Delcroix JD; Belichenko PV; Zhan K; Wu C; Valletta JS; Takimoto-Kimura R; Kleschevnikov AM; Sambamurti K; Chung PP; Xia W; Villar A; Campbell WA; Kulnane LS; Nixon RA; Lamb BT; Epstein CJ; Stokin GB; Goldstein LS; Mobley WC
    Neuron; 2006 Jul; 51(1):29-42. PubMed ID: 16815330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NGF Metabolic Pathway in the CNS and its Dysregulation in Down Syndrome and Alzheimer's Disease.
    Iulita MF; Cuello AC
    Curr Alzheimer Res; 2016; 13(1):53-67. PubMed ID: 26391047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human brain NGF metabolic pathway is impaired in the pre-clinical and clinical continuum of Alzheimers disease.
    Pentz R; Iulita MF; Ducatenzeiler A; Bennett DA; Cuello AC
    Mol Psychiatry; 2021 Oct; 26(10):6023-6037. PubMed ID: 32488129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome.
    Granholm AC; Sanders LA; Crnic LS
    Exp Neurol; 2000 Feb; 161(2):647-63. PubMed ID: 10686084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease.
    Cuello AC; Bruno MA
    Neurochem Res; 2007 Jun; 32(6):1041-5. PubMed ID: 17404842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential deregulation of NGF and BDNF neurotrophins in a transgenic rat model of Alzheimer's disease.
    Iulita MF; Bistué Millón MB; Pentz R; Aguilar LF; Do Carmo S; Allard S; Michalski B; Wilson EN; Ducatenzeiler A; Bruno MA; Fahnestock M; Cuello AC
    Neurobiol Dis; 2017 Dec; 108():307-323. PubMed ID: 28865749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation.
    Cuello AC; Bruno MA; Allard S; Leon W; Iulita MF
    J Mol Neurosci; 2010 Jan; 40(1-2):230-5. PubMed ID: 19680822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ProNGF\NGF imbalance triggers learning and memory deficits, neurodegeneration and spontaneous epileptic-like discharges in transgenic mice.
    Tiveron C; Fasulo L; Capsoni S; Malerba F; Marinelli S; Paoletti F; Piccinin S; Scardigli R; Amato G; Brandi R; Capelli P; D'Aguanno S; Florenzano F; La Regina F; Lecci A; Manca A; Meli G; Pistillo L; Berretta N; Nisticò R; Pavone F; Cattaneo A
    Cell Death Differ; 2013 Aug; 20(8):1017-30. PubMed ID: 23538417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype.
    Allard S; Leon WC; Pakavathkumar P; Bruno MA; Ribeiro-da-Silva A; Cuello AC
    J Neurosci; 2012 Feb; 32(6):2002-12. PubMed ID: 22323714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galaninergic innervation of the cholinergic vertical limb of the diagonal band (Ch2) and bed nucleus of the stria terminalis in aging, Alzheimer's disease and Down's syndrome.
    Mufson EJ; Cochran E; Benzing W; Kordower JH
    Dementia; 1993; 4(5):237-50. PubMed ID: 7505157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer's Cholinergic Atrophy.
    Do Carmo S; Kannel B; Cuello AC
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome.
    Iulita MF; Caraci F; Cuello AC
    CNS Neurol Disord Drug Targets; 2016; 15(4):434-47. PubMed ID: 26996175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levels of phospholipid catabolic intermediates, glycerophosphocholine and glycerophosphoethanolamine, are elevated in brains of Alzheimer's disease but not of Down's syndrome patients.
    Blusztajn JK; Lopez Gonzalez-Coviella I; Logue M; Growdon JH; Wurtman RJ
    Brain Res; 1990 Dec; 536(1-2):240-4. PubMed ID: 2150771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery.
    Nagahara AH; Bernot T; Moseanko R; Brignolo L; Blesch A; Conner JM; Ramirez A; Gasmi M; Tuszynski MH
    Exp Neurol; 2009 Jan; 215(1):153-9. PubMed ID: 19013154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.